# Dr. Reddy's: how the business works

> For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Dr. Reddy's Laboratories Limited · NYSE: RDY · Sector: Health Care

Updated for Q2 FY2027 · checked Nov 18, 2026

This is the plain-text version of https://cityfort.co/stocks/dr-reddys-adr. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Dr. Reddy's: how the business works", with the page URL.

## The 30-second summary

Dr. Reddy's, a drug maker based in Hyderabad, India, earned INR 335,933 million of revenue and INR 42,850 million of profit for equity holders in FY2026 (year ended Mar 31, 2026). North America revenue fell 22% that year, which the company linked mainly to lower lenalidomide sales and a one-time claim. In Q2 FY2027, revenue was INR 86,708 million and profit for equity holders INR 9,250 million.

## 5 points

- **What it sells:** Dr. Reddy's sells generic and branded medicines and drug ingredients; its Global Generics segment brought in INR 299,033 million of FY2026 revenue of INR 335,933 million. [S1]
- **Who pays it:** North America paid 33.9% of FY2026 revenue, India 18.5%, Europe 16.5%, Russia 10.4%, other CIS countries and Romania 2.7%, the rest of the world 7.1%, ingredient and service buyers 10.4% and others 0.6%. [S1]
- **What it keeps from INR 100:** Of every INR 100 that came in during FY2026, including INR 12,277 million of other income, net finance income, its share of associates' profit and the minority partner's losses, Dr. Reddy's kept INR 12.3 as profit; operating profit, which included one-off trademark and settlement gains, was INR 15.0 per INR 100 of revenue. [S1]
- **Where the operating profit comes from:** Dr. Reddy's reports segment profit only down to gross profit: Global Generics earned INR 169,698 million of FY2026's INR 177,264 million, PSAI INR 5,984 million and Others INR 1,582 million. [S1]
- **The one thing to watch:** North America revenue was INR 24,890 million in Q2 FY2027, against INR 32,408 million a year earlier, while emerging markets revenue rose to INR 20,595 million from INR 16,548 million. [S7]

## What does Dr. Reddy's sell?

Dr. Reddy's makes copies of medicines whose patents have expired, called generics, and sells them in North America, Europe and emerging markets. It also sells branded medicines in India and Russia, and drug ingredients to other drug makers.

- **Global Generics: finished medicines:** Medicines sold as generics or under brand names, including biosimilars and quit-smoking brands. The segment brought in INR 299,033 million, 89.0% of FY2026 revenue. [S1]
- **Generics in North America:** Generic tablets, injectables and store-brand over-the-counter products: INR 113,737 million in FY2026, down 22%. The company said in its Q4 FY2026 release that the fall was mainly due to lower lenalidomide sales and a one-time claim. [S1, S10]
- **Nicotine replacement brands:** Nicotinell, Nicabate and related quit-smoking products outside the US, bought from Haleon in September 2024. They brought in INR 28,189 million in FY2026. [S1]
- **Branded medicines in India and emerging markets:** India revenue was INR 62,186 million in FY2026, up 16%, and Russia INR 34,786 million. IQVIA ranked Dr. Reddy's 10th by sales in India, with a 3.2% share, the 20-F says. [S1]
- **Drug ingredients and contract services (PSAI):** Active pharmaceutical ingredients (API), the main ingredient in a medicine, sold to other drug makers, plus contract research and manufacturing. External revenue was INR 34,773 million in FY2026. [S1]

## Who pays Dr. Reddy's?

- **North America (33.9% of revenue):** Mostly retail chains, wholesalers and private-label customers. Revenue was INR 113,737 million in FY2026, down 22% from FY2025. [S1]
- **India (18.5% of revenue):** Sold through agents to about 6,500 wholesalers, who sell on to retailers. Revenue was INR 62,186 million, up 16%. [S1]
- **Europe (16.5% of revenue):** Revenue was INR 55,501 million, up 55%, including INR 28,189 million from the nicotine replacement brands bought from Haleon. [S1]
- **Russia (10.4% of revenue):** Revenue was INR 34,786 million in FY2026. [S1]
- **Other CIS countries and Romania (2.7% of revenue):** Revenue was INR 9,074 million in FY2026. [S1]
- **Rest of the world (7.1% of revenue):** Revenue was INR 23,749 million in FY2026. [S1]
- **Drug makers buying ingredients and services (PSAI) (10.4% of revenue):** External revenue was INR 34,773 million, not counting INR 7,270 million sold to Dr. Reddy's own Global Generics unit. [S1]
- **Others (0.6% of revenue):** INR 2,127 million, mainly from Aurigene Oncology, a drug-discovery subsidiary, and proprietary products. [S1]
- **Customer concentration:** Shares are of FY2026 revenue by market (Cityfort calculation from the FY2026 20-F). In North America, most revenue comes from retail chains, wholesalers and private-label customers; in India, Dr. Reddy's sells to about 6,500 wholesalers. [S1]

## Where the money went (FY2026)

1. Customers paid Dr. Reddy's INR 335,933 million in FY2026 for medicines, drug ingredients and services.
2. Making the products cost INR 158,669 million, leaving gross profit of INR 177,264 million.
3. Selling, general and administrative costs took INR 106,763 million, research INR 24,058 million and write-downs INR 3,519 million.
4. Other income of INR 7,627 million included INR 1,890 million from selling trademarks and INR 1,400 million from lawsuit settlements. Operating profit was INR 50,551 million.
5. Finance income and associates added INR 4,266 million and income tax took INR 12,351 million. With the minority partner's INR 384 million share of losses, INR 42,850 million was left for equity holders.

Sources: S1.

## Key numbers by year (INR million)

Financials: consolidated, INR million. Fiscal years are the company's own: Mar 31 (fiscal 2026 = Apr 1, 2025 to Mar 31, 2026). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (INR per equity share, as filed) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY2022 | 214,391 | 41,300 | 19.3% | 23,568 | 11.0% | — | 28,108 | 14,660 | 13,448 | S5 |
| FY2023 (restated) | 245,879 | 69,780 | 28.4% | 45,067 | 18.3% | 54.17 | 58,875 | 11,323 | 47,552 | S4, S2 |
| FY2024 (restated) | 279,164 | 82,570 | 29.6% | 55,684 | 19.9% | 66.8 | 45,433 | 16,403 | 29,030 | S1 |
| FY2025 | 325,535 | 88,901 | 27.3% | 56,544 | 17.4% | 67.78 | 46,428 | 27,504 | 18,924 | S1 |
| FY2026 | 335,933 | 71,156 | 21.2% | 42,850 | 12.8% | 51.42 | 56,755 | 23,326 | 33,429 | S1 |

- EBITDA here = operating income plus depreciation and amortization (from the cash flow statement).
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of Sep 30, 2026, INR million)

At Sep 30, 2026, Dr. Reddy's had INR 76,242 million of cash and current investments against borrowings of INR 58,260 million, not counting leases: net cash of INR 17,982 million (Cityfort calculation from the Q2 FY2027 Form 6-K). [S6, S7, S1]

| Item | Value |
| --- | --- |
| Total debt | 58,260 |
| Cash and investments | 76,242 |
| Net debt (debt minus cash) | −17,982 |
| Net worth (shareholders' money) | 386,179 |
| Debt to equity (times) | 0.15 |

- Cash and current investments is a Cityfort calculation from the Q2 FY2027 Form 6-K: cash of INR 13,294 million plus current investments of INR 62,948 million. Non-current investments of INR 10,428 million are left out.
- Lease liabilities of INR 14,027 million are not counted as debt here; with them, borrowings were INR 72,287 million at Sep 30, 2026.
- Dr. Reddy's own measure, "net cash surplus", was INR 25,024 million at Sep 30, 2026. It leaves out lease liabilities, restricted cash and equity investments, and counts non-current investments.
- Borrowings including leases rose from INR 46,766 million at Mar 31, 2025 to INR 77,341 million at Mar 31, 2026. Short-term borrowings rose from INR 38,045 million to INR 59,135 million.
- Equity attributable to equity holders was INR 386,179 million at Sep 30, 2026. Other intangible assets, mostly product rights and brands, were INR 105,059 million at Mar 31, 2026.

## Who owns Dr. Reddy's? (as of Mar 31, 2026)

Each equity share carries one vote, and there is one class of shares. The FY2026 20-F says the full-time executive directors and their immediate families beneficially owned 26.63% of issued shares at Mar 31, 2026. BlackRock reported 5.3% at Sep 30, 2024 and 4.1% at Mar 31, 2025 in its Schedule 13G filings. [S1, S14, S15, S16]

| Class | Shares (millions) | Votes per share | % of shares | % of votes | Traded | Sources |
| --- | --- | --- | --- | --- | --- | --- |
| Equity shares (834,656,970 shares at Mar 31, 2026. At Sep 30, 2026, 834,680,285 shares were issued, including 1,607,435 treasury shares held by an employee stock option trust: 833,072,850 net. The shares trade in India; ADSs trade on the New York Stock Exchange, one ADS per share.) | 834.66 | 1 | 100.0% | 100.0% | Yes | S1, S8 |

Holders of 5% or more (each row shows the date of its own filing):

| Holder | Shares | Votes | As of | Note | Sources |
| --- | --- | --- | --- | --- | --- |
| The K. Satish Reddy and G.V. Prasad families and their trusts | 26.63% | — | Mar 31, 2026 | 222,305,640 shares, including the GVP Family Trust (11.51%), with G.V. Prasad among its trustees, and the VSD Family Trust (9.06%), with K. Satish Reddy among its trustees. A Schedule 13D/A filed on Sep 18, 2025 reported transfers into the trusts on Sep 17, 2025. | S1, S14 |
| Life Insurance Corporation of India and associates | 12.16% | — | Mar 31, 2026 | 101,502,343 shares, up from 7.19% at Mar 31, 2025 and 5.05% at Mar 31, 2024. | S1 |
| J.P. Morgan Chase Bank, N.A. (depositary) | 11.94% | — | Mar 31, 2026 | Holds the equity shares behind the ADSs, according to the FY2026 20-F. | S1 |

## What could go wrong

### A few products can move results

The 20-F says a limited number of products may account for a significant portion of revenue. North America revenue fell 22% in FY2026, which the company linked mainly to lower lenalidomide sales and a one-time claim. [S1, S10, S7]

What to watch: North America revenue each quarter: INR 24,890 million in Q2 FY2027, against INR 32,408 million a year earlier.

### Falling prices for US generics

The 20-F says new manufacturers keep entering the US generic market, which may further lower its pricing power. Price changes cut Global Generics revenue by about 10% in FY2026, including the lenalidomide claim. [S1]

What to watch: Price, volume and new-product effects in the next 20-F's segment review.

### Manufacturing and quality

Semaglutide batches found out of specification led to an INR 2,397 million provision in Q1 FY2027. A separate Canada recall reduced Q2 FY2027 revenue by INR 710 million, booked as expected returns. [S6, S7]

What to watch: Results of the US FDA inspections at the two Indian sites, reported in the 6-K releases.

### Business in Russia

Russia brought in INR 34,786 million, 10.4% of FY2026 revenue. Dr. Reddy's booked INR 1,836 million in FY2026 after a Federal Tax Service VAT audit of one of its foreign subsidiaries. It believes "the likelihood of any further liability that may arise on account of this field tax audit is not probable". [S1, S9]

What to watch: Russia's revenue and the company's notes on geopolitical conflicts in each 6-K.

### Rupee and other currencies

Much of Dr. Reddy's revenue is in US dollars, euros, rubles, pounds and Brazilian reals, while much of its costs are in rupees, the 20-F says. FY2026 revenue rose 3% as reported but fell 2% excluding currency moves. [S1]

What to watch: Reported growth against growth excluding currency moves in each 20-F.

### US drug pricing rules and tariffs

The 20-F says US drug pricing changes, including most-favored-nation requirements, and tariffs could hurt its prices and costs. North America brought in 33.9% of FY2026 revenue. [S1]

What to watch: US pricing and tariff rules and the company's comments on them in its 6-K releases.

### US price-fixing lawsuits

Lawsuits combined in a Philadelphia federal court since 2016 allege that certain US generic makers conspired on prices from about 2009. Dr. Reddy's US subsidiary is a defendant; the company believes the claims are "without merit", denies any wrongdoing and has made no provision. [S1]

What to watch: Test trials expected in late 2026 or 2027, the 20-F says; in two of them the subsidiary is named for three drugs in total.

### Two families' influence

The founding families and their trusts held 26.63% of shares at Mar 31, 2026. The 20-F says their influence could delay or prevent a change in control. [S1, S14]

What to watch: The families' holding in the next 20-F and any Schedule 13D amendment.

## What to watch

Next: Q3 FY2027 results (quarter ending Dec 31, 2026), Date not announced yet.

- **North America after lenalidomide:** North America revenue was INR 24,890 million in Q2 FY2027, up from INR 22,048 million in Q1 FY2027 and down from INR 32,408 million a year earlier.
- **Semaglutide:** Generic semaglutide was approved in 10 countries by Oct 23, 2026. The Q1 FY2027 provision was INR 2,397 million and the Q2 FY2027 Canada recall INR 710 million.
- **Margins:** Operating profit per INR 100 of revenue was INR 14.6 in Q2 FY2027, against INR 19.9 a year earlier and INR 1.8 in Q4 FY2026.

## Sources

- S1: Form 20-F for FY2026 (year ended March 31, 2026). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587526000381/rdy0899_20f.htm (published May 29, 2026)
- S2: Form 20-F for FY2025 (year ended March 31, 2025). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587525000393/rdy-20250331.htm (published Jun 6, 2025)
- S3: Form 20-F for FY2024 (year ended March 31, 2024). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587524000660/rdy-20240331.htm (published Jun 12, 2024)
- S4: Form 20-F for FY2023 (year ended March 31, 2023). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587523000951/rdy-20230331.htm (published Jun 13, 2023)
- S5: Form 20-F for FY2022 (year ended March 31, 2022). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587522000576/rdy-20220331.htm (published Jun 27, 2022)
- S6: Form 6-K: Q2 FY2027 results under IFRS (Exhibit 99.3). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587526000725/rdy0952_ex99-3.htm (published Oct 23, 2026)
- S7: Form 6-K: Q2 FY2027 earnings release (Exhibit 99.2). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587526000725/rdy0952_ex99-2.htm (published Oct 23, 2026)
- S8: Form 6-K: Q2 FY2027 report (interim condensed consolidated financial statements). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587526000719/rdy0950_6k.htm (published Oct 23, 2026)
- S9: Form 6-K: Q4 FY2026 results under IFRS (Exhibit 99.3). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587526000301/rdy0894_ex99-3.htm (published May 12, 2026)
- S10: Form 6-K: Q4 FY2026 earnings release (Exhibit 99.2). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587526000301/rdy0894_ex99-2.htm (published May 12, 2026)
- S11: Form 6-K: Q3 FY2026 results under IFRS (Exhibit 99.2). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587526000034/rdy0840_ex99-2.htm (published Jan 21, 2026)
- S12: Form 6-K: Q1 FY2026 results under IFRS (Exhibit 99.3). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587525000483/rdy0780_ex99-3.htm (published Jul 23, 2025)
- S13: Form 6-K: Q1 FY2026 earnings release (Exhibit 99.2). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/Archives/edgar/data/1135951/000157587525000483/rdy0780_ex99-2.htm (published Jul 23, 2025)
- S14: Schedule 13D/A (Amendment No. 6) by G.V. Prasad, K. Satish Reddy and family trusts. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1135951/000157587525000580/xslSCHEDULE_13D_X01/primary_doc.xml (published Sep 18, 2025)
- S15: Schedule 13G/A (Amendment No. 1) by BlackRock, Inc.. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1135951/000205211325001826/xslSCHEDULE_13G_X01/primary_doc.xml (published Apr 28, 2025)
- S16: Schedule 13G by BlackRock, Inc.. SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1135951/000201238324002294/ine089a01023_102424.txt (published Oct 24, 2024)
- S17: Form F-6 registration of American Depositary Shares (stock split). SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1135951/000119380524001270/e663969_f6-drreddy.htm (published Oct 23, 2024)
- S18: RDY historical daily prices, Nov 2 to Nov 16, 2026 (Nasdaq.com table for the NYSE-listed ADS; close of Nov 16, 2026: $14.70). Nasdaq, Inc.. https://api.nasdaq.com/api/quote/RDY/historical?assetclass=stocks&fromdate=2026-11-01&todate=2026-11-17&limit=20 (published Nov 17, 2026)
- S19: EDGAR filing index for Dr. Reddy's Laboratories Ltd (CIK 0001135951). Dr. Reddy's Laboratories Limited (SEC EDGAR). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001135951&type=&dateb=&owner=include&count=100 (published Nov 16, 2026)
